Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inhalon Biopharma

Request full access

Develops inhalation therapies for respiratory diseases

Morrisville, United StatesFounded 2018Biotech & Life Sciences

About Inhalon Biopharma

Inhalon Biopharma, Inc. operates as a clinical-stage biotechnology firm, established in 2018, with a focus on developing inhaled immunotherapies for acute respiratory infections (ARIs). The company was founded by Dr. Sam Lai, who also serves as the Chief Scientific Officer. Dr. Lai, a professor at the University of North Carolina at Chapel Hill, has a research background in pharmacoengineering and molecular pharmaceutics, particularly in delivering molecules to mucosal tissues. His work on "muco-trapping" antibodies, which earned him a Packard Fellowship and an NSF CAREER Award, forms the technological basis of the company. John Whelan was appointed CEO in 2019 and leads the company alongside Dr. Lai.

Inhalon’s core business revolves around its proprietary technology platform that enables inhaled antibodies to trap pathogens like viruses and bacteria within the lung's mucus. This mechanism prevents the pathogens from infecting cells and leverages the body's natural mucus clearance process to rapidly eliminate them. The process involves specially engineered antibodies that bind to both the pathogen and mucins, the primary glycoproteins in mucus. These trapped pathogens are then cleared from the lungs within 30 to 60 minutes. The company's business model centers on the development and eventual commercialization of these novel biologic treatments. Its clients are patients suffering from ARIs for which there are currently limited or no approved treatments. The company aims for its therapies to be self-administered by patients using a handheld nebulizer, which could reduce the burden on healthcare facilities.

The company's product pipeline targets several significant respiratory viruses, including respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and SARS-CoV-2. A key candidate, IN-006, developed for COVID-19, completed a Phase 1 study in 2022, demonstrating it could be safely delivered to volunteers with prolonged lung retention. The company is also advancing IN-002 for RSV and IN-007 for SARS-CoV-2. Inhalon has secured significant non-dilutive funding through grants and awards from organizations like the U.S. Army Medical Research & Development Command (USAMRDC) and the National Institutes of Health (NIH) to advance its clinical programs. Since its first funding round in November 2019, the company has raised capital through private equity and numerous grants, totaling over $45 million by early 2025, to fund its research and move candidates through clinical trials.

Source: Dealroom company data

Inhalon Biopharma in the Morrisville ecosystem

Live from Dealroom

The Inhalon Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Sand Hill Angels
  • Life Science Angels
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inhalon Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inhalon Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.